Workflow
Artificial Intelligence in Drug Discovery
icon
Search documents
Renovaro Secures Key U.S. Patent to Strengthen AI-Driven Drug Discovery and Diagnostics Platform
Globenewswire· 2025-06-03 13:15
Core Insights - Renovaro Inc. has received a Notice of Allowance for a new patent that enhances its AI and machine learning capabilities in drug discovery [1][2] - The patent focuses on integrating diverse biomedical data sources into a standardized framework for predictive modeling, addressing a critical need in the biopharma industry [2][4] - This development is seen as a strategic milestone for Renovaro, reinforcing its position in the growing market for data-driven therapeutics [3][4] Company Overview - Renovaro aims to accelerate precision and personalized medicine through AI and biotechnology platforms, focusing on early diagnosis and targeted treatments [5] - The company includes subsidiaries such as RenovaroBio, which specializes in cell-gene immunotherapy, and RenovaroCube, which leverages AI for multi-omic diagnostics [5] Patent Details - The new patent introduces methods for real-time, reproducible predictive analytics across distributed computing environments, essential for improving efficiency in biopharma [4][7] - This patent builds on a previously granted patent that protects machine learning pipeline optimization, enhancing Renovaro's foundational intellectual property [7] Market Implications - The patent addresses the integration of siloed and heterogeneous data, a significant challenge in pharmaceutical R&D and clinical practice [7] - It enhances Renovaro's commercial potential by enabling scalable biomedical analytics across various applications, including rare diseases and personalized medicine [7]
Nurix Therapeutics to Participate in the Jefferies Global Healthcare Conference
Globenewswire· 2025-05-28 11:00
Core Insights - Nurix Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on targeted protein degradation medicines aimed at improving treatment options for cancer and inflammatory diseases [3] - The company will participate in a fireside chat at the Jefferies Global Healthcare Conference on June 4, 2025, featuring its president and CEO, Arthur T. Sands, M.D., Ph.D., and CFO, Hans van Houte [1] Company Overview - Nurix's pipeline includes degraders of Bruton's tyrosine kinase (BTK) and inhibitors of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), with a focus on enhancing immune cell activation [3] - The company is advancing multiple potentially first-in-class or best-in-class degraders and degrader antibody conjugates (DACs) in its preclinical pipeline [3] - Nurix has partnered with Gilead Sciences, Sanofi, and Pfizer, retaining options for co-development, co-commercialization, and profit sharing in the U.S. for several drug candidates [3] - The company utilizes a fully AI-integrated discovery engine and has significant expertise in ligase, providing a competitive advantage in translating targeted protein degradation into clinical advancements [3]
Preliminary Phase 1b/2 Data for REC-4881 in Familial Adenomatous Polyposis (FAP) Demonstrates Reduced Polyp Burden
Globenewswire· 2025-05-04 16:45
Core Insights - Recursion announced preliminary safety and efficacy results from its Phase 1b/2 TUPELO trial of REC-4881, an investigational MEK1/2 inhibitor for Familial Adenomatous Polyposis (FAP) [1][5] Company Overview - Recursion is a clinical-stage TechBio company focused on decoding biology to improve lives, utilizing its Recursion OS platform to analyze biological and chemical datasets [23] - The company has received Fast Track and Orphan Drug designations from the U.S. FDA for REC-4881, which is aimed at treating FAP, a rare inherited disorder [2] Clinical Trial Details - The TUPELO trial is evaluating the safety, tolerability, pharmacokinetics, and preliminary efficacy of REC-4881 in patients with FAP [6][8] - The Phase 1b portion was a randomized, double-blind, placebo-controlled safety run-in, while the ongoing Phase 2 portion is open-label [7][8] Efficacy Results - As of March 17, 2025, REC-4881 treatment led to a preliminary median 43% reduction in polyp burden at Week 13 among six efficacy-evaluable patients [3][10] - Five out of six patients (83%) experienced reductions in polyp burden ranging from 31% to 82%, while one patient showed a 595% increase from baseline [3][10] - Three of six patients (50%) achieved a ≥1-point reduction in Spigelman stage, indicating improvement in disease severity [11] Safety Profile - Among 19 safety-evaluable patients, 79% experienced at least one treatment-related adverse event (TRAE), with the majority being Grade 1 or 2 [4][16] - The most frequent TRAEs included acneiform rash, diarrhea, and decreased left ventricular ejection fraction (LVEF) [4][17] - Grade 3 TRAEs occurred in 16% of patients, with no Grade ≥4 events reported [4][18] Next Steps - Patient enrollment in the TUPELO trial is ongoing, with additional efficacy and safety analyses anticipated in the second half of 2025 [21]
英矽智能完成1.1亿美元E轮融资,加速人工智能与机器人驱动的药物研发创新
IPO早知道· 2025-03-14 10:52
英矽智能在人工智能平台开发和药物研发管线建设方面取得了显著进展。 本文为IPO早知道原创 据IPO早知道消息,英矽智能日前已完成由惠理集团(HKG: 0806)旗下私募股权基金、浦东创投 和浦发集团、锡创投和宜兴国控联合领投的1.1亿美元E轮融资。本轮融资还吸引了专注于行业和科 技领域的新晋投资者的参与,并得到了现有投资者的支持。 本轮融资所募得的资金将用于推动英矽智能在人工智能平台升级和药物研发管线创新方面的突破。一 方面,资金将用于完善英矽智能专有的人工智能模型和算法,同时升级和扩展其领先的自动化机器人 实验室,以进一步实现和优化研发流程的自动化。另一方面,英矽智能将专注于推进其用于治疗特发 性肺纤维化(IPF)的核心候选药物的临床验证,并加速对其他自主研发和合作开发的药物管线的探 索,加速在生物医药研发领域的突破性创新。 过去一段时间,英矽智能在人工智能平台开发和药物研发管线建设方面取得了显著进展,以真实世界 案例验证了其自主研发的AI驱动平台在药物研发早期阶段显著降低成本和提高效率的能力。如已对外 公布的其自主研发临床前候选药物(PCC)的关键基准所示, 通过集成先进的人工智能和自动化技 术,英矽智能 ...